VPA

DRUG2 trials

Sponsors

University Hospital Freiburg, Shanghai Jiao Tong University School of Medicine

Conditions

Acute Myeloid LeukemiaPeripheral Blood Stem Cell TransplantationaGVHD

Phase 2

Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia

CompletedNCT00867672

University Hospital FreiburgAcute Myeloid Leukemia

Start: 2011-08-31End: 2016-02-29Updated: 2016-08-31

Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD

Shanghai Jiao Tong University School of MedicineaGVHD, Peripheral Blood Stem Cell Transplantation

Start: 2016-07-31End: 2019-12-31Target: 55Updated: 2016-08-01

Related Papers

Impact of <i>TP53</i> Mutation Status in Elderly <scp>AML</scp> Patients When Adding All‐<i>Trans</i> Retinoic Acid or Valproic Acid to Decitabine

European Journal Of Haematology2024-10-135 citations

Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.

2024-09-112 citations

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics.

2023-11-283 citations

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-<i>Trans</i> Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Blood2022-11-15

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation

Blood Cancer Journal2022-08-2219 citations

Randomized Phase II Study of All-<i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status

Blood2021-11-053 citations

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Blood2018-11-296 citations

In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?

Blood2018-11-29

Cooperative Effects of a Dnmt Inhibitor and All-Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Blood2018-11-29

Preferential In Vitro and In Vivo Induction of Endogenous Retrovirus Transcription from a Monoallelic Chromosome 7q in Decitabine (DAC) Treated AML Blasts

Blood2017-12-07

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Blood2016-12-0216 citations

Combination Treatment of AML Cells with Dnmt and HDAC Inhibitors: Synergistic Target Gene Downregulation Associated with Gene Body Demethylation

Blood2015-12-03

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.

2015-05-2636 citations

In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response

Blood2014-12-06

Synergistic Reactivation Of Cancer/Testis Antigens By Combination Treatment With Decitabine and Histone Deacetylase Inhibitors (Valproate, Panobinostat) In Myeloid Leukemia Cells

Blood2013-11-15